VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy

Overview of attention for article published in Cancer Immunology Research, June 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,835 followers.

Adap: VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.: Related Articles… http://t.co/TSFiI390mR

Nice review of checkpoint ab inhibitors in trials for #cancer #immunotherapy: http://t.co/GKsUUFkViD via @AACR @KingsCollegeLon

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.